Early experience with recombinant interferon alfa-2b in chronic hepatitis C (HCV) has shown that normalisation of serum alanine aminotransferase activities and reduction in hepatic inflammation can be achieved in about 40% of patients. This occurs with loss ofviral replication as measured by polymerase chain reaction for HCV-RNA. Further studies are needed to identify patients most likely to respond to treatment and to investigate the issues of non-response and relapse when treatment is stopped. Alternative interferon treatment regimens, as well as other drugs and combinations of agents, need to be investigated. (Gut 1993; supplement: S109-S11 1)
Pilot studies
In the 1980s, there were several case reports describing the treatment of chronic non-A, non-B hepatitis with interferon (IFN).1 2 It was not until 1986, however, that the first systematic study of this form of treatment in well-characterised patients with chronic non-A, non-B hepatitis was reported by Hoofnagle and associates at the National Institutes of Health Liver Unit. 3 In that study, 10 patients were treated with recombinant interferon alfa2b at an initial dose of 5 million units (MU) daily (in most patients), with the dose decreased, as tolerated, to the lowest dose which would maintain a normal serum alanine aminotransferase activity. Serum alanine aminotransferase fell quickly to normal in six of 10 patients (complete response) and the rapidity of the alanine aminotransferase decrease suggested a direct antiviral effect. Surprisingly, this initial response was maintained after treatment was stopped in five of six patients who responded.
US studies
The encouraging results in the National Institutes of Health pilot study led to the implementation of several randomised controlled trials, including a placebo controlled study which was conducted by Di Bisceglie and colleagues, also at the National Institutes of Health.4 This trial compared a dose of 2 MU interferon alfa-2b, given subcutaneously three times per week for six months, with placebo given in the same schedule. Interestingly, although more than 60% of patients treated with IFN normalised their serum alanine aminotransferase at some point during the treatment period, breakthrough of serum alanine aminotransferase to abnormal values was common and such that only 33% maintained a normal alanine aminotransferase value at the end of treatment. In addition, most patients responding to treatment relapsed after treatment was stopped. This suggested that higher doses or treatment of a longer duration, similar to that used in the pilot study, might be more efficacious.
The United States multicentre study (Hepatitis Interventional Therapy group study) later confirmed the dose response effect of IFN treatment. 5 In this large study, the probability of complete response was 38% in patients treated with a dose of 3 MU interferon alfa-2b three times weekly, but only 16% in those treated with 1 MU, and 4% in untreated controls (Fig 1) . Histological improvement was seen in the 3 MU group and was characterised by reduction of lobular inflammation and a trend towards improvement of periportal inflammation (Fig 2) . Interestingly, compared with Di Bisceglie's report, breakthrough in serum alanine aminotransferase was not seen. This study formed the basis for the licensing of interferon alfa-2b for the treatment of HCV (INTRON A; Schering-Plough) in the United States.
Comparison with European studies Two European studies using an almost identical study design to the United States study subsequently reported a very similar complete response rate (normal alanine aminotransferase), and also showed a similar proportion of patients with histological improvement. 
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Goals of treatment
Interferon is an antiviral agent which suppresses HCV replication below detectable values in patients responding to treatment. '7 Relapse occurs in 50-80% of patients, however, after treatment has stopped.5-8 Thus, eradication of HCV is an uncommon event and, with the treatment regimens in current use, is not an appropriate goal of treatment. Treatment for patients who have relapsed has been shown to be effective in inducing response again;5 however, the most appropriate method of a further course of treatment has not been studied. The two logical alternatives for further treatment are to repeat the six month course which was successful originally, or to start long term treatment at the lowest dose which will maintain response. There are few or no data to support either of these alternatives at the present time. It is important, if long term treatment is considered, that we have a marker for the endpoint of treatment. These markers are likely to be virological but have not yet been identified.
Summary and conclusions
In summary, studies to date have shown clearly that recombinant interferon alfa-2b treatment of chronic HCV is -ffective. Normalisation of serum alanine amin0transferase and reduction of hepatic inflammation can be achieved in approximately 40% of patients.58 This is associated with loss of HCV replication, as measured by the polymerase chain reaction for HCV-RNA in liver and serum. '8 Several outstanding issues remain despite these achievements. The natural history of the disease needs clarification so that appropriate patients can be selected for treatment. Fewer than 50% of patients respond to current regimens, so patients most likely to respond to IFN and those most in need of treatment to alleviate the course of their disease must be identified and offered treatment. Other interferon regimens, different drugs, and combinations of drugs need to be tested as alternate regimens for patients not responding to treatment or those predicted to have poor response. Finally, markers of successful and permanent treatment response need to be identified.
There have been many major basic and clinical accomplishments in the field of HCV research over the last few years. There is still much more to be achieved. 
